Investigator Surgical Oncology Program, National Cancer Institute Bethesda, Maryland, United States
Though impressive responses have been realized with current immune checkpoint blockade immunotherapies, many solid tumors, and specifically GI/HPB cancers, have remained resistant. New and ongoing trials utilizing bispecific antibodies and adoptive cell therapies are revealing promise for the treatment of these cancers. The purpose of this session is to update the audience on novel antibodies and T-cell therapies for these diseases and the role of the surgical oncologist in developing and utilizing these technologies.
